Aurora Cannabis Inc. to Acquire CanniMed Therapeutics Inc. in Friendly Deal

Aurora Cannabis Inc. (TSX:ACB) finally got its deal after months of battling with CanniMed Therapeutics Inc. (TSX:CMED).

| More on:
win

After months of drama, it looks like the cannabis industry’s soap opera is finally ending. It was announced on Wednesday that Aurora Cannabis Inc. (TSX:ACB) had reached a friendly deal to acquire CanniMed Therapeutics Inc. (TSX:CMED) for a value of $1.1 billion.

Previously, Aurora sought to acquire CanniMed in a hostile takeover after its first attempt at a friendly deal failed to succeed. After a public feud that involved CanniMed filing a lawsuit against Aurora for damages as a result of the takeover, the tide started to turn last week. Rumours were swirling that Aurora was looking to purchase both Newstrike Resources Ltd. (TSXV:HIP) as well as CanniMed, but under a friendly deal again.

However, Newstrike has been left out in the cold on this one, as CanniMed has agreed to abandon its acquisition of Newstrike, which will require it to pay $9.5 million in fees.

Big improvement in the offer

After initially offering $24 a share for CanniMed, Aurora has agreed to pay $43 a share under this deal, which amounts to an increase of nearly 80%. CanniMed shareholders that hung on for the ride were rewarded handsomely; in three months, the stock grew from less than $12 to now being valued at $43 for an increase of more than 265% in just three months.

Did Aurora pay too much?

CanniMed has just $15 million in revenue in the trailing 12 months, and it has posted losses of $28 million during that time as well. At a $1.1 billion valuation, Aurora has paid a multiple of ~73 times CanniMed’s annual sales, which is actually not high for a cannabis industry, where we’ve seen multiples north of 100.

Although it may seem high to investors, given the industry’s high values and what Aurora believes CanniMed can add to the table, it’s a bit surprising, but it shouldn’t be shocking.

What does this mean for the industry?

Now that CanniMed and Aurora are one big happy family, Canopy Growth Corp. (TSX:WEED) is now in danger of losing its place as the top pot stock in the industry and as overall market leader. Recently, we’ve seen Canopy’s stock start to slow down, and that could be a sign that it is leveling off and has reached a ceiling at ~$37.

In trading on Wednesday, Canopy’s stock was down 2%, as investors may have decided to jump ship to its competitors. Investors may be wondering why the company is not planning to make a big splash with an acquisition itself; after all, there are plenty of opportunities to do so in what’s become a very fragmented industry.

The Aurora-CanniMed deal is the biggest acquisition we’ve seen so far in the early days of the pot industry, and there are still likely more deals to come.

Perhaps most intriguing is what will happen with Newstrike. The company, which must feel like it has been the third wheel in a spat between Aurora and CanniMed, has been left out in the cold. It could be an opportunity for one of the other big players in the industry, whether it’s Canopy or perhaps MedReleaf Corp. (TSX:LEAF), which focuses on medicinal marijuana, to swoop in and acquire the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Investing

A worker gives a business presentation.
Investing

Where Will Saputo Stock Be in 1/3/5 years?

Here's where dairy giant Saputo (TSX:SAP) could be headed over the near to medium term.

Read more »

Man data analyze
Bank Stocks

Is TD Bank Stock a Buy, Sell, or Hold for 2025?

TD stock has underperformed its large Canadian peers this year. Will 2025 be different?

Read more »

young people stare at smartphones
Dividend Stocks

GST/HST “Vacation”: Everything Canadians Need to Know

The GST/HST "vacation" is a little treat for the holidays, along with a $250 payment. What should you do with…

Read more »

oil pump jack under night sky
Energy Stocks

Where Will CNQ Stock Be in 3 Years?

Here’s why CNQ stock could continue to outperform the broader market by a huge margin over the next three years.

Read more »

BCE stock
Tech Stocks

10% Yield: Is BCE Stock a Good Buy?

The yield is bigger than it's ever been in the company's history. That might not be a good thing.

Read more »

3 colorful arrows racing straight up on a black background.
Investing

1 Canadian Stock Ready to Surge Into 2025

Canadian Natural Resources (TSX:CNQ) stock is a sleeping dividend giant that may be about to wake up.

Read more »

Tractor spraying a field of wheat
Investing

Is Nutrien Stock a Buy for its 4.7% Dividend Yield?

Nutrien (TSX:NTR) is a well-known defensive commodities play. But is this stock worth buying for its dividend yield alone?

Read more »

Happy shoppers look at a cellphone.
Tech Stocks

So You Own Shopify Stock: Is it Still a Good Investment?

Shopify (TSX:SHOP) stock has had a run, but there's still room to the upside.

Read more »